LGND Q1 2020 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M-23.7% YoY

Gross Profit

$28M85.9% margin

Operating Income

$4M11.4% margin

Net Income

-$24M-72.8% margin

EPS (Diluted)

$-1.46

QoQ Revenue Growth

+22.8%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$524M

Stockholders' Equity

$662M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$43M	-23.7%
Gross Profit	$28M	$40M	-28.1%
Operating Income	$4M	$827M	-99.5%
Net Income	-$24M	$666M	-103.6%

Revenue Segments

MaterialSalesCaptisolMember

$21M50%

Royalty

$7M16%

Kyprolis

$4M11%

Service

$3M8%

Contract Revenue

$2M5%

Evomela

$2M4%

LicenseFeesMember

$975,0002%

LicenseFeesMilestonesandProductOtherProductOtherMember

$821,0002%

Royalty, Other

$584,0001%

MilestoneMember

$334,0001%